The future belongs to those who believe in multiplex CAR T engineering.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40614711.
- Also identified by DOI 10.1016/j.stem.2025.06.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Toxicity and immune evasion have hindered the success of CAR T cells in HER2-positive solid tumors. In this issue of Cell Stem Cell, Hosking et al. present an iPSC-derived CAR T cell product engineered for tumor-selective targeting, resistance to the immunosuppressive tumor microenvironment, enhanced persistence and trafficking, and mitigation of antigen escape.
Medical subject headings
- Receptors, Chimeric Antigen
- Immunotherapy, Adoptive
- T-Lymphocytes